<DOC>
	<DOCNO>NCT01824992</DOCNO>
	<brief_summary>ass efficacy safety recombinant human interferon α-2b gel ( Yallaferon® ) treatment patient cervical high-risk HPV infection ; analyze HPV type infection clinical negative conversion . 285 patient positive high risk HPV infection randomize interferon gel group control group ratio 2:1 ( 203 patient treatment group 82 patient control group ) . The patient treatment group receive 1g recombinant human α-2b interferon gel every day consecutive 3 course treatment , whereas treatment conduct control group .</brief_summary>
	<brief_title>Recombinant Human Interferon a-2b Gel HPV Gynecological Infections</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<criteria>1 . Age 30 65 year age sex life female patient ; 2. , liquidbased cytology ( TCT ) check intraepithelial lesion malignant cell ; 3. , HPV DNA type test highrisk HPV positive ( include single highrisk type positive , highrisk type positive highand lowrisk hybrid positive ) . 15 kind highrisk type , include HPV16 , 18,31,33,35,39,45,51,52,53,56,58,59,66,68 ( 1 ) cervical intraepithelial neoplasia ( CIN ) ; ( 2 ) , combine severe fungal , trichomonas vaginitis ; ( 3 ) , severe primary disease associate cardiovascular , liver , kidney hematopoietic system ; ( 4 ) , allergies allergy drug know ingredient . ( 5 ) , within 30 day accept clinical trial drug participate clinical trial ; ( 6 ) , pregnant lactate woman pregnant woman ; ( 7 ) , researcher consider appropriate clinical trial .</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>